XWAR
NNG
Market cap26mUSD
Oct 07, Last price
2.42PLN
1D
-0.41%
1Q
-0.82%
IPO
-43.06%
Name
Nanogroup SA
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
14.40%
Rev. gr., 5y
-64.09%
Revenues
0
-100.00%
Net income
-9m
L+82.77%
CFO
-9m
L+53.88%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
NanoGroup S.A. operates as a biotechnology company in Poland. It engages in the production of medicines and other pharmaceutical products, and research and development work in the field of biotechnology and other natural and technical sciences. The company is also involved in technical research and analysis. In addition, it manages a portfolio of companies that manage projects to meet the needs of modern medicine in the field of oncology and transplantology. The company was founded in 2016 and is based in Warsaw, Poland.
Key people
Przemyslaw Mazurek
President of the Management Board · since 2024
Piotr Mierzejewski
Vice-President of the Management Board · since 2024
Stefan Boguslawski
Member of the Management Board · since 2022
Tomasz Ciach
Member of the Management Board, Founder
Jerzy Garlicki
Chairman of the Supervisory Board · since 2021
Lukasz Golebiewski
Independent Member of the Supervisory Board · since 2025
Independent Member of the Supervisory Board · since 2025
Jose Arrieta
Member of the Supervisory Board · since 2024
Pawel Ciach
Member of the Supervisory Board · since 2021
Robert Dziulowski
Member of the Supervisory Board · since 2021
Member of the Supervisory Board · since 2017
Member of the Supervisory Board · since 2017
Headquarters & legal address
Warszawa Rakowiecka 36
Warszawa, 14 02-532
PL
Warszawa, 14 02-532
PL
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||